BORA PHARMACEUTICALS CO Stock Price, News & Analysis

Bora Pharmaceuticals Co., Ltd. (BORAY) operates as a pharmaceutical manufacturing company and contract development and manufacturing organization serving commercial drug products and pharmaceutical partners. The company is associated with Taiwan-listed shares under 6472.TW and an OTCQX-traded security under BORAY. Its disclosed operations include global commercial manufacturing, development support, and product supply services for established pharmaceutical products.

Bora’s CDMO business includes manufacturing work for pharmaceutical partners across multiple therapeutic areas. At its Mississauga facility, which Bora purchased from GSK in 2020, the company provides end-to-end manufacturing services for commercial product lines and individual products used in areas that include infectious disease, mental health, dermatology, migraine, and other conditions. The company’s manufacturing network also includes an oral solid dose site in Maple Grove, Minnesota, used within its broader pharmaceutical production infrastructure.

Through Upsher-Smith Laboratories, LLC, a Bora subsidiary, the company also participates in the U.S. prescription pharmaceutical market. Upsher-Smith’s activities include launches of generic and branded prescription products, differentiated dosage forms, and patient and healthcare professional support resources tied to specific medicines. Its disclosed products include KYMBEE (deflazacort) Tablets, indicated for Duchenne muscular dystrophy in patients 5 years of age and older, and Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, a generic version of Ciprodex.

Bora’s business model combines contract manufacturing services for external pharmaceutical companies with product commercialization through its operating subsidiary. Its disclosures emphasize commercial-scale manufacturing, oral solid dose capabilities, product launches, portfolio diversification, and access-support programs connected to prescribed therapies.